LivaNova (Nasdaq:LIVN) today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary ...

The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea (OSA ... data to the U.S. Food and Drug Administration (FDA) ...

It's been more than a year since Apple Watch Ultra 2 launched, and we've had the wearable that's only gotten better on our ...

Inc. (NYSE: INSP) (“Inspire,” or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive ...

The Galaxy Watch is the most mainstream of Samsung's ranges and is designed to compete directly with the Apple Watch. The ...

Do you suffer from sleep apnea and long for a peaceful night’s sleep and solution to your snoring? Holy Cross Medical Group pulmonologist Ronald Scott, M.D. will speak about Inspire®, an FDA-approved ...

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with ...

Inspire Medical Systems shares are up today on third-quarter results that came in ahead of the consensus forecast.

Inspire Medical Systems topped Q3 expectations, signaling continued market strength and innovation.

Inspire is increasing its full year 2024 revenue guidance to between $793 million to $798 million, which represents growth of 27% to 28% over full year 2023 revenue of $624.8 million. This compares to ...